Research
Hormonal
GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.
Practitioners can consider GLP-1 receptor agonists as effective treatment options for managing glycemic levels and reducing complications in type 2 diabetes patients.
StrongSupportsmedium confidence
GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.
Why this rating
The claim is based on landmark trials and current data discussed in the abstract.
Source
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
Lidiya Kukova et al. · Expert Opinion on Drug Metabolism & Toxicology · 2024
DOI 10.1080/17425255.2024.2401589
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →